A new 'In Discussion With' episode covers the dangers of buying unlicensed retatrutide for weight loss, a drug still in trials.
Recap by typeshit. Post by Facebook on Facebook.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
A surgeon on social media says the FDA has received two death reports involving black-market retatrutide. No official FDA statement is linked.
Bhekisisa points out that local treatment guidelines now recommend GLP-1s for obesity, while the price keeps them out of reach for many.
A basic explainer on Lilly's experimental drug retatrutide and what it is used for. Little detail beyond the question itself.
Loading…